Guofeng Lou

> 15 years on Drug development; 7+ years on Clinical project; 8+ years on Pre-clinical research 

My academic studies and research experiences developed and cemented my interest in many areas of science and particularly in human disorders and therapeutics, while also building solid foundation for my further career. Through my current role as a Clinical Program Manager / Senior Medical Advisor Europe at Fosun Pharma, and my previous role as a Clinical Project Lead / Medical Scientist at Oslo University Hospital, as well as my part-time work experience as a Clinical Biomarker Project Lead at Aladdin Healthcare Technologies; I accumulated and expanded my pharmaceutical industry knowledge, working on pre-clinical/clinical and translational medicine projects. I have accomplished many high-quality projects using my extensive global networking skills and my proven project management skills in cross-functional teams. I am very passionate about using my drive, knowledge and networking skills to lead and accomplish innovative projects and deliver the best medicinal products to patients.

2021.01 to Present

Clinical Program Manager / Senior Medical Advisor Europe 

Fosun Pharma, China/Germany

Leading the clinical projects about drug development and clinical diagnosis of human disorders (focus on CNS-disease and Oncology) in the Fosun Pharma Europe branch.

2018.01 to 2020.12 

Clinical Project Lead / Medical Scientist 

Oslo University Hospital (UiO/AHUS), Norway

Mainly worked on the following projects (Including Pre-Clinical and Clinical research/projects): - The interconnected roles of NAD+ depletion, compromised mitophagy, and APOE4 in the etiology and progression of Alzheimer's disease (AD) - Novel clinical biomarkers for AD early-diagnosis

- The pre-clinical and clinical studies for the treatment of neurodegenerative diseases:

• AD (Collaboration with Copenhagen U/Novo Nordisk, Denmark): Phase 2, 3

• PD (Collaboration with UiB, Norway): Phase 1, 2

• ALS (Collaboration with NIH, USA): Phase 1, 2

- Artificial intelligence (AI)/Machine learning (ML)-based approach identifies potent mitophagy inducers that ameliorate AD pathology

2019.01 to 2020.12

Clinical Biomarker Project Lead (Part-time)

Aladdin Healthcare Technologies SE, Norway/UK

Led the collaboration project between Aladdin and UiO/AHUS: Non-invasive early detection/diagnosis of AD via retinal imaging, and related to cognitive functions, as well as the clinical biomarker development.

2016.09 to 2017.12 

Postdoctoral Researcher / Clinical Research Associate 

Department of Neuroscience, Uppsala University, Sweden

> Main researcher of the project "Investigations on VAAT, a novel transport protein in the brain, and the role in depression" supported by the Brain Foundation in Sweden.

2015.08 to 2016.08

Senior Research Associate (Specialization in Neuro-medicine)

Biopharmaceutical Research & Development Center

Jinan University, China

Key Work Experiences:

• Worked on the project about AD drug candidates screening;
• Planned, conducted and made publications of the research project;
• Coordinated with several pharmaceutical companies for the project collaboration.

2012.09 to 2015.07

Doctor of Philosophy (Ph.D) Specialization in Biomedicine

Institute of Biomedicine & Department of Cell Biology,

Jinan University, China

Doctoral Thesis Title: Intranasal administration of TAT-haFGF improves neurodegeneration in the APP/PS1 and SAMP8 mouse models of s disease as well as the mechanism research

> Completed the major project "Alzheimer's disease drug candidate - Research and discovery of modified recombinant human acidic fibroblast growth factor (rhaFGF)" supported by the National Science and Technology Major Project of the Ministry of Science and Technology in China.

2009.09 to 2012.07

Master of Medicine (M.Med) in Biochemical Pharmacy

College of Pharmacy, Jinan University, China

2005.09 to 2009.07

Bachelor of Medicine (B.Med) in Pharmacy,

College of Pharmacy, Jining Medical University, China